Drug Interactions between cholestyramine and divalproex sodium
This report displays the potential drug interactions for the following 2 drugs:
- cholestyramine
- divalproex sodium
Interactions between your drugs
cholestyramine divalproex sodium
Applies to: cholestyramine and divalproex sodium
ADJUST DOSING INTERVAL: Cholestyramine may interfere with the gastrointestinal absorption of valproic acid and reduce its bioavailability. In six study subjects, administration of a single 250 mg dose of valproic acid simultaneously with a 4 gram dose of cholestyramine (given twice daily starting one day before valproic acid administration) resulted in an average 15% decrease in valproic acid peak serum concentration and 21% decrease in systemic exposure (AUC) compared to administration alone. By contrast, no significant interaction was observed when valproic acid was given 3 hours before the cholestyramine dose. The bioavailability of valproic acid, relative to administration alone, was 86.2% when given concurrently with cholestyramine and 95.3% when given 3 hours before cholestyramine.
MANAGEMENT: To minimize potential for interaction, oral valproic acid and cholestyramine should be administered at least 3 hours apart. Patients should be monitored for clinical and laboratory evidence of altered valproate efficacy, and the dosage adjusted if necessary. It is not known whether these precautions are applicable to extended-release valproic acid or divalproex formulations.
References (8)
- (2001) "Product Information. Depakene (valproic acid)." Abbott Pharmaceutical
- Malloy MJ, Ravis WR, Pennell AT, Diskin CJ (1996) "Effect of cholestyramine resin on single dose valproate pharmacokinetics." Int J Clin Pharmacol Ther, 34, p. 208-11
- (2024) "Product Information. Divalproex Sodium Sprinkles (divalproex sodium)." Ajanta Pharma USA
- (2024) "Product Information. Dyzantil (valproate)." Aspire Pharma Ltd
- (2018) "Product Information. Valpro (valproate)." Alphapharm Pty Ltd
- (2024) "Product Information. Valproic Acid (valproic acid)." ANI Pharmaceuticals, Inc.
- (2023) "Product Information. Cholestyramine (cholestyramine)." Chartwell RX, LLC.
- (2024) "Product Information. Colestyramine (colestyramine)." Neon Healthcare Ltd
Drug and food interactions
divalproex sodium food
Applies to: divalproex sodium
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References (4)
- Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
- (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
- (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
cholestyramine food
Applies to: cholestyramine
ADJUST DOSING INTERVAL: Bile acid sequestrants and the phosphate binder, sevelamer, can decrease the absorption of fat-soluble vitamins A, D, E, and K. By binding bile acids, these agents may interfere with normal fat digestion and absorption, thereby preventing the absorption of fat-soluble vitamins. When 8 grams of cholestyramine was administered simultaneously with a normal meal containing 250,000 units of vitamin A acetate in four healthy young adult subjects, plasma vitamin A levels were significantly reduced during a 9-hour postprandial period compared to the values obtained with the control meal. Coadministration with 4 grams of cholestyramine had no significant effect. In a crossover study involving healthy subjects, coadministration of sevelamer with calcitriol resulted in a significant reduction in bioavailability for calcitriol (calcitriol with sevelamer vs calcitriol alone: AUC 137 pg*h/mL vs 318 pg*h/mL and Cmax 40.1 pg/mL vs 49.7 pg/mL, respectively). Chronic use of bile acid sequestrants has been rarely associated with an increased bleeding tendency due to hypoprothrombinemia resulting from vitamin K deficiency. Isolated cases of Vitamin A (including one case of night blindness) and D deficiencies have also been reported with chronic cholestyramine therapy.
MANAGEMENT: When bile acid sequestrants are given for prolonged periods, some manufacturers recommend that concomitant supplementation with water-miscible or parenteral forms of fat-soluble vitamins be considered. If oral vitamin supplements are used with cholestyramine or colestipol, advise patients to take them at least 1 hour before or 4 to 6 hours after the bile acid sequestrant to minimize the potential impact on their absorption. No recommendations are available for sevelamer, but it may be advisable to follow the same precautions.
References (11)
- Gross L, Brotman M (1970) "Hypoprothrombinemia and hemorrhage associated with cholestyramine therapy." Ann Intern Med, 72, p. 95-6
- Shojania AM, Grewar D (1986) "Hypoprothrombinemic hemorrhage due to cholestyramine therapy." Can Med Assoc J, 134, p. 609-10
- Longstreth GF, Newcomer AD (1975) "Drug-induced malabsorption." Mayo Clin Proc, 50, p. 284-93
- Acuna R, Gonzalez Ceron M (1977) "Hypoprothrombinemia and bleeding associated to treatment with cholestyramine (author's transl)." Rev Med Chil, 105, p. 27-8
- (2001) "Product Information. Rocaltrol (calcitriol)." Roche Laboratories
- (2001) "Product Information. Welchol (colesevelam)." Daiichi Sankyo, Inc.
- (2005) "Product Information. Fosamax Plus D (alendronate-cholecalciferol)." Merck & Co., Inc
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
- Peirce D, Hossack S, Poole L, et al. (2011) "The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol." Nephrol Dial Transplant, 26, p. 1615-21
- Vroonhof K, van Rijn HJM, van Hattum J (2003) "Vitamin K deficiency and bleeding after long-term use of cholestyramine." Neth J Med, 61, p. 19-21
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.